- Home
- CYCN vs XCUR Comparison
CYCN vs XCUR Comparison
Compare CYCN & XCUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CYCN | XCUR |
|---|---|---|
| Founded | 2018 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.6M | 13.7M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | CYCN | XCUR |
|---|---|---|
| Price | $3.49 | $1.58 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 18.5K | ★ 239.4K |
| Earning Date | 05-08-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 83.37 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.03 | $1.43 |
| 52 Week High | $8.48 | $9.48 |
Technical Indicators
Market Signals| Indicator | CYCN | XCUR |
|---|---|---|
| Relative Strength Index (RSI) | 45.10 | 34.94 |
| Support Level | $2.93 | $1.43 |
| Resistance Level | $3.97 | $2.02 |
| Average True Range (ATR) | 0.17 | 0.22 |
| MACD | -0.04 | 0.02 |
| Stochastic Oscillator | 14.72 | 22.31 |
Price Performance
Historical ComparisonAbout CYCN Cyclerion Therapeutics Inc.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. The company focuses on enabling the full therapeutic potential of next-generation sGC stimulators and neuropsychiatric diseases. Its pipeline products include Olinciguat, Praliciguat, and others.
About XCUR Exicure Inc.
Exicure Inc is a clinical-stage biotechnology company focused on developing treatments for blood-related diseases, with an emphasis on small-molecule therapies that have the potential to benefit a broad range of patients. The company acquired GPCR Therapeutics USA and secured a license for GPC-100 (Burixafor), a clinical-stage small-molecule compound that inhibits the chemokine receptor CXCR4. GPC-100 has demonstrated the ability to effectively mobilize various cell types, including hematopoietic stem cells and lymphocytes, highlighting its broad therapeutic potential across multiple indications.